The NHS will invest nearly $7 million in AI tools to enhance prostate MRI performance and early cancer detection.
Key Details
- 1The NHS is allocating almost $7 million to AI solutions for prostate MRI, as part of a wider $20 million investment.
- 2Lucida Medical will receive over $3 million, and Quibim (Spain) will get $3.5 million to deploy prostate AI tools.
- 3Quibim's QP-Prostate software will be rolled out in seven English hospitals over two years.
- 4The project aims to increase the rate of early-stage prostate cancer diagnoses from 50% to 75% by 2028.
- 5Prostate cancer is the most common cancer in UK men, with over 52,000 new cases and 12,000 deaths annually.
Why It Matters
Investing in AI-enhanced MRI interpretation could significantly increase early detection rates of prostate cancer, potentially improving patient outcomes. This major NHS rollout signals strong institutional confidence in AI’s role in clinical radiology practice.
Source
Radiology Business
Related News
•AI in Healthcare
Nvidia, Amazon Drive AI Expansion Across Genomics and Radiology
Major healthcare and technology companies partner to push AI advancements in genomics, radiology, and broader healthcare.
•AuntMinnie
Multimodal MRI Radiomics Model Predicts Long-Term Survival in Breast Cancer
A multimodal MRI radiomics and deep learning model outperformed traditional models in predicting 5- and 7-year survival for breast cancer patients receiving neoadjuvant chemotherapy.
•AuntMinnie
AI Streamlines and Lowers Costs in Breast MRI Screening
An AI-based protocol for breast MRI screening improves access and reduces costs by optimizing scan times.